You are here: Industry Insights > AbbVie

News List

Or can they? AbbVie puts endometriosis options on display in first Orilissa ad fiercepharma
January 23, 2019
AbbVie’s first campaign for Orilissa is a play on the brand name for the endometriosis pain drug.
Or can they? AbbVie puts endometriosis options on display in first Orilissa ad fiercepharma
January 23, 2019
AbbVie’s first campaign for Orilissa is a play on the brand name for the endometriosis pain drug.
AbbVie and J&J’s Imbruvica fails pancreatic cancer test pharmaphorum
January 23, 2019
AbbVie and Johnson & Johnson’s hopes of adding pancreatic cancer to the repertoire of oncology blockbuster Imbruvica has hit a snag.
Johnson & Johnson, AbbVie superstar Imbruvica flunks pancreatic cancer test fiercepharma
January 22, 2019
AbbVie and Johnson & Johnson’s blockbuster Imbruvica is approved to treat six diseases, but it looks like pancreatic cancer won’t be its seventh.
Court backs NHS in hepatitis C procurement row with AbbVie pharmaphorum
January 22, 2019
A court has backed NHS England in a case where US pharma giant AbbVie had alleged that its procurement process for hepatitis C drugs was unfair.
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory? fiercepharma
January 08, 2019
Bristol-Myers Squibb’s Thursday announcement that it would nab Celgene for $74 billion brought “megamergers back to pharma,” as Credit Suisse analyst Vamil Divan put it in a note to clients. And the return has industry watchers wondering which company wil
Billions spent, but AbbVie can't catch a break with Rova-T as it cans SCLC trial fiercebiotech
January 02, 2019
AbbVie announced Wednesday afternoon that it would stop enrollment in a phase 3 trial of its troubled cancer med, Rova-T, in lung cancer patients.....
Lupin and AbbVie Announce Partnership to Develop and Commercialize Novel Oncology Drug to Treat Hematological Cancers pharmafocusasia
December 27, 2018
Pharma major Lupin Limited (Lupin) and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program......
Lupin in partnership with AbbVie en-cphi.cn
December 26, 2018
To develop and commercialise a novel oncology drug to treat haematological cancers
AbbVie seeks US and European authorisations for upadacitinib pharmaceutical-technology
December 24, 2018
AbbVie has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), seeking approvals for .....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page